Connor Clark & Lunn Investment Management Ltd. Purchases New Position in Natera, Inc. (NASDAQ:NTRA)

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 72,128 shares of the medical research company’s stock, valued at approximately $9,157,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NTRA. Covestor Ltd boosted its holdings in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC lifted its position in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares during the last quarter. CIBC Asset Management Inc boosted its stake in Natera by 3.3% during the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after buying an additional 111 shares during the period. RiverPark Advisors LLC boosted its stake in Natera by 3.5% during the third quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after buying an additional 112 shares during the period. Finally, Moss Adams Wealth Advisors LLC increased its position in Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after acquiring an additional 135 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 256 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the transaction, the insider now owns 111,891 shares in the company, valued at $13,434,752.37. This represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at $25,141,737.28. This trade represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,503 shares of company stock valued at $6,325,804 in the last 90 days. Insiders own 7.60% of the company’s stock.

Natera Stock Up 0.8 %

Natera stock opened at $169.20 on Friday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market cap of $22.34 billion, a P/E ratio of -96.14 and a beta of 1.53. The business has a fifty day moving average of $129.84 and a two-hundred day moving average of $117.00. Natera, Inc. has a twelve month low of $53.62 and a twelve month high of $171.95.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.95) earnings per share. On average, analysts forecast that Natera, Inc. will post -1.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the subject of several analyst reports. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. The Goldman Sachs Group boosted their target price on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Leerink Partners increased their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price objective on Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Finally, Canaccord Genuity Group lifted their target price on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $140.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.